|
Dr Brian Hargreaves,
Global Sector Head – Healthcare Brian joined 3i in 1997 after nearly twenty years in the pharma industry. He started his career as a Lecturer in Pharmacy at Manchester University before switching to pharma with SmithKline & French, and has since had a series of senior, international corporate and commercial roles with Mundipharma, Wellcome and most recently Astra Hässle. He has been involved in the development of major brands such as Zovirax (POM to P switch) and Nexium ($4bn annual sales). He chairs the Sector Investment Committee and has a global responsibility across the portfolio. He is a member of Pharmaceutical Licensing Group, Licensing Executives Society and Industrial Pharmacist’s Group. He is also a member of the Royal Pharmaceutical Society. Brian is a PhD Pharmacist. He has participated in the Executive Management Course (INSEAD). |
 |
| Tim
McCarthy, MBA FCCA, Finance Director Mr McCarthy is a co-founder of Alizyme. He is a qualified accountant and gained an MBA from Cranfield School of Management in 1988. He has held senior financial positions in a number of multinational companies. He has been instrumental in the start up and early stages of development of a number of biotechnology companies over the last 10 years, including being the founding finance director of Peptide Therapeutics Group plc (now Acambis plc) until April 1995. Mr McCarthy is also Company Secretary of Alizyme plc and has overall responsibility for the Group’s financial, investor relations and business development matters. |
 |
| Dr.
Chris Henderson, Director Global
Licensing Chris joined the pharmaceutical industry in 1980 when he left an academic post as a Lecturer in pharmacology and went to Pfizer Central Research in Sandwich, Kent. Chris had a CV research management role at both Pfizer and Zeneca Pharmaceuticals (formerly ICI) for more than 10 years. Chris’s next appointment was as Collaborations Manager within a newly formed group charged with establishing new R&D collaborations with Academia and the Biotech Industry. Chris joined Product Licensing at Zeneca in 1996 and is now responsible within AstraZeneca Global Licensing, as part of a dedicated "Japan Team", for interactions including deal-making with Japanese-based pharmaceutical companies across all therapy areas as well as for “deal-making” in the Cardiovascular Therapy Area. He has managed Licensing Teams responsible for deals of many different types with a wide range of partners. |
 |
| Jöel
Besse, Senior Partner Joël Besse is a Senior Partner in the life sciences sector, and joined Atlas Venture in 1995. After serving as an auditor at Arthur Andersen and at Crédit Lyonnais in Paris, he began his career in venture capital in 1991 with SED Ventures, a firm specializing in international life sciences investments. At Atlas Venture, he was a founding investor in Actelion Pharmaceuticals Ltd. (SWX:ATLN), where he currently sits on the board, and Novuspharma S.p.A. (acquired by Cell Therapeutics in 2003). In addition to his current board seats (see below) Joël has also served on the boards of Axovan A.G. (acquired by Actelion Pharmaceuticals in 2003), Entomed S.A., Immuno-Designed Molecules S.A., Neurotech S.A., Laboratoires Effik S.A. (listed on Euronext in 1999 and acquired by Italfarmaco and Liconsa in 2003) and Modex Thérapeutiques S.A. (now Isotis S.A., SWX:ISO). Joël holds a Master of Science degree from the University of Toulouse and graduated from Ecole Nationale Supérieure de I’Aéronautique et de l’Espace. Board participation includes: |
 |
| Dr.
rer. nat. Markus Metzger, Senior
Analyst Biotech Markus Metzger is a molecular/cell biologist. His doctoral thesis was about the molecular biology of yeast (University of Düsseldorf). He was a postdoctoral research fellow in molecular immunology at the Harvard Medical School in Boston, a scientific research fellow in molecular and cellular immunology at the University Medical School in Ulm and an industry research fellow for biotechnology in microtechnology at the Institute of Microtechnology in Mainz. Markus Metzger joined Bank Vontobel as a pharmaceutical/biotech research analyst in 1999 and is based in Cologne. |
| Dr.
Tilman Dumrese, Biotech
Analyst Tilman Dumrese is an immunobiologist (Dr. rer. nat.). After completing his studies at the University of Tübingen and the California State University in San Francisco, he worked as a researcher in the areas of cancer and infectious diseases. Following his doctoral thesis in 1998 (Strategies for the Identification of T Cell Epitopes, German Cancer Research Center Heidelberg, University of Tübingen) he joined the Institute of Experimental Immunology at the University of Zurich as a postdoctoral research fellow. Tilman Dumrese joined Bank Vontobel AG as a biotech research analyst in April 2002. |
 |
| Hoda
Abou-Jamra, Founder & CEO During the course of her career, Ms. Abou-Jamra has established a solid network of contacts in U.S. Biotechnology and venture capital firms. Before founding BioExec Ventures, LLC, Ms. Abou-Jamra was in business development at Acumen Sciences, a research firm for the biotechnology and pharma industries. Previous to Acumen, she held a business development position at Incyte Genomics. Before joining Incyte she was involved in the early stage of Pure Tech Ventures, which creates and develops companies based on innovative life science technologies that often represent the convergence of several areas of research and development. Her past bio/pharma experience includes a successful sales, Marketing and Business Development position at Boiron Laboratories and Bayer Corporation. Prior to that she lead NPC Inc., a private consulting firm specializing in business, marketing, and fundraising. In addition to her career pursuits, Ms. Abou-Jamra has also served on several finance and fundraising committees, including Senator John Kerry's campaign finance committee and service as a board member for the Massachusetts Women's Political Caucus. She is also a member of the Academy of Managed Care Pharmacists, American Pharmaceutical Association, the Fenway Community Health Center and BIO Business Forum Committee and the International Subcommittee. Ms. Abou-Jamra graduated from the Bouve College of Health Sciences, Northeastern University with a degree in Pharmacy. |
 |
| Dr.
Morris S. Berrie, CEO Since March 2003 Dr. Berrie has been the Chief Executive and Editor-in-Chief of Biotechnology Investment Today. Immediately prior to this he consulted for several well-known companies operating in the Life Science sector. Previously he was Nature Publishing Group’s Head of Global Intelligence and Business Development and responsible for the research and development of key product launches. He originally started his media / publishing career at Current Drugs (now Thomson Current Drugs) where managed the life science patent and drug registry content of the Investigational Drug database (IDdb). He has worked at Schering AG, is a Chartered Chemist, a Member of the Royal Society and was the recipient of a European DG Post-Doctoral Fellowship upon completing his Ph.D. at Imperial College, London. He currently sits on the Business, Publishing and Awards Committees of the Royal Society of Chemistry and Industry. |
| Dr.
Jonathan D. Turner, Head of Corporate
Department, Pharmaceutical Licensing After an academic career teaching in Psychiatry, Dr Turner joined industry with Schering AG, managing drug discovery in CNS research for 10 years before joining Astra in 1997. At Astra and AstraZeneca he has fulfilled roles in collaboration, alliance management and in-licensing in multiple indications. Having joined Boehringer Ingelheim in 2002, he has global responsibility for clinical and preclinical phase in-licensing opportunities and potential alliances to support and extend the Boehringer Ingelheim portfolio. |
 |
| Susan
Flynn, Partner Prior to joining Coller Capital, Susan was Chief Executive Officer, General Motors Asset Management (UK), part of the General Motors Investment Management Corporation; a member of General Motors Global Private Markets Group; Associate Director, Bioscience Department, Rothschild Asset Management in London; Manager, Membership Department, Investment Management Regulatory Organisation (subsequently absorbed into the Financial Services Authority); Chief Financial Officer, GTE Insurance Company Limited, London. Susan is a qualified Chartered Accountant, Institute of Chartered Accountants of England and Wales; with a BSc in Pure Mathematics and Geography, Sheffield University. Susan is previously a Director of the Private Equity Investors Association. She has also sat on various private equity advisory boards, including Alchemy Partners, Apax Partners, BC Partners and Nordic Capital. |
| Spiro
Rombotis, CEO Spiro Rombotis, CEO, joined Cyclacel in August 1997. He has 21 years of experience with pharmaceutical and biotech companies. Previously Vice President, International Operations & Business Development, Managing Director, Europe and Director Japanese joint venture, The Liposome Company, Inc.; Vice President, Pharmaceuticals, Central & Eastern Europe and Director International Marketing, Bristol-Myers Squibb Company; Head European Marketing and Sales, Head Corporate Development, Centocor, Inc.; Business Development, Novartis AG. BA, Williams College. MBA and Master's degree in Hospital Management with honors, Kellogg Graduate School of Management, where he serves on the Advisory Board, Kellogg Center for Biotechnology. |
 |
| Dimitri
Dimitriou, Chief Executive Officer Dimitri F. Dimitriou, has over 17 years experience in healthcare in corporate transactions / business development, general management, marketing, sales, finance and R&D, both in the pharma and biotech sectors. He received his first degree in Biochemistry from the University of London prior to graduating in Pathology & Toxicology from the Royal Postgraduate Medical School in London in 1984. He began his career in the pharmaceutical industry as Product Manager in Marketing at Sandoz (Novartis) and was recruited in 1989 into Procter & Gamble, where he spent around 8 years in managerial positions including overall responsibility for Sales and Marketing for the pharmaceutical business in Asia, and later, Finance, Clinical Development of anti-infectives, and heading Medical Information prior to eventually concentrating in Licensing and Acquisitions as Business Development Manager-Europe. Dimitri joined SmithKline Beecham in 1996 as Associate Director and was appointed Director, Worldwide Business Development in 1998 and Senior Director in January 2000. His responsibilities included worldwide transactions - licensing deals, alliances and collaborations with pharmaceutical and biotech companies. In his role at SmithKline Beecham and GlaxoSmithKline, he routinely handled identification of opportunities, commercial assessment and due diligence, development of deal structures, and agreement negotiations. In 2001, he left GSK to move to the biotech sector as CEO of the London-based drug discovery company Xcellsyz and in addition set up DyoDelta Biosciences, a company providing support in licensing, corporate and financing transactions. In mid-2002, Dimitri joined Bristol-Myers Squibb setting up and heading the Business Development function in Europe, responsible for the full array of business development opportunities on a global basis with a focus on deals with European companies, before leaving a few months later to return to DyoDelta Biosciences. Dimitri has managed approx. 25 executed collaborations, having been involved in over 100 partnering projects over the past 8 years. He is a regular speaker in partnering conferences and also a member of the Convocation of the University of London, the Licensing Executives Society, the Pharmaceutical Licensing Group, British Mensa and the Chairman of the Advisory Board of Pharmalicensing. |
 |
| Marc
Perret, Director Marc-Olivier Perret is a Director of Gilde Biotech & Nutrition Fund, a pan-European fund managed by Dutch-based Gilde Investment Management. The fund focuses on Healthcare investments in early stage companies. Marc’s last investment was Innate Pharma (cancer immunotherapeutics, France). He is a member of the Boards of BioProtein Therapeutics (France) and Crop Design (Belgium). Before joining Gilde in late 2000, Marc gathered a 15 year international experience in operations, business development and Mergers & Acquisitions at Ciba/Novartis. In his last position, as head of M&A and Strategic Planning of Novartis Crop Protection worldwide, he managed – and was actively involved in – all aspects of the most sizeable M&A and BD projects (due diligence, negotiations, anti-trust). Marc is an engineer from Ecole Centrale de Lyon and holds a MBA from HEC Group. |
 |
| Dr.
Steven Powell, Director
Steven Powell is a Director of Gilde Biotech & Nutrition Fund, a pan-European fund managed by Dutch-based Gilde Investment Management. The fund focuses on Healthcare investments in early stage companies. Steven graduated in Microbiology from the University of Wales and was awarded a Ph.D from the University of Aberdeen. He has worked in the pharmaceutical and biotechnology industry since ‘85 in both technical and commercial management roles, initially with Beecham Pharmaceuticals (now Glaxo SmithKline) as a development scientist and subsequently with Whatman, Radiometer, Chiroscience and Active Biotech. He joined Gilde in 2003 from KS Biomedix plc, a UK quoted biopharmaceutical company, where he was CEO until its acquisition by Xenova Group plc. Steven’s last investment was in Chroma Therapeutics (cancer drug development, UK) and he also represents Gilde on the Board of Inpharmatica. |
 |
| Dr.
Peter Reinisch, Partner Dr. Peter H. Reinisch is a Partner of Global Life Science Ventures. He has over 21 years experience in the life science industry that include senior management positions in the Corange group and from 1995 onwards the setting up of GLS I. He is a board member, or attendee, with a number of portfolio companies, five of which are already public — four by initial public offering, one by merger. Prior to Corange/Boehringer Mannheim Dr.Reinisch held positions of increasing responsibility with Brown Boveri, the Institute for Automation, the Denner Group and McKinsey and Co., where he concentrated on high technology industries. He became CEO of Pfister, one of his clients. Dr. Reinisch first studied mechanical engineering, then graduated summa cum laude with a doctorate degree in Business Administration (Betriebswissenschaften) from the Technical University of Vienna. |
 |
| Willi
Meier, CEO Willi Meier, CEO of “Greater Zurich Area AG”, the marketing organization for the “Greater Zurich Area”. Prior to his assignment mid 2001 he held several managerial positions in international marketing and sales in the Chemical and Pharmaceutical Industry and in the Food Industry. 5 years of his professional career he spent in Asia. His professional background is a university degree in business administration and marketing. |
 |
| Dr.
Andreas Wicki, CEO Education: Professional history: Mandates: |
 |
| Seth
Yakatan, Partner Seth has over 12 years of experience as a corporate finance professional in the United States and over 3 years of experience in venture capital investing as an analyst with both the Ventana Growth Funds and Sureste Venture Management. Most recently, Seth worked with Union Bank of California, N.A., in the media and telecommunications group. While there, he completed numerous debt financings totaling in excess of several billion dollars while placing subordinated debt and private equity into several portfolio companies on behalf of the bank. In the past three years as a Co-Founder of Katan, Seth has successfully managed sell-side M&A engagements for companies in the Life Science space, generating aggregate transaction value in excess of $40.0 million. Additionally, as part of Katan, Seth has been responsible for closing several early-stage partnering assignments, with aggregate value generated for clients in excess of $250.0 million. Seth serves as a board member for Technoprises/Apros & Chay Ltd. Seth holds a MBA in Finance from the University of California, Irvine and a BA in History and Public Affairs from the University of Denver. |
 |
| Stan
Yakatan, Chairman After 30 years as a successful CEO, entrepreneur,and operational manager, Stan Yakatan has dedicated the last 7 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive and in several instances serving as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch, provided him with management and corporate finance acumen that he enjoys sharing with others. He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada). He has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, "Capital Raising for the Technology-Based Start-Up" and "The Need to be Global in the Quest for Capital and Partners". Rick Biondi, Editor of Lab Business Magazine stated," Mr Yakatan is a venture capital raising Guru and it is part of his genetic make up." He currently serves as the strategic advisor to the state government of Victoria, Australia and is the Chairman of Katan Associates International with headquarters in New York City. |
 |
| Sandrine
Cailleteau, Head of Corporate Business
Development & Licensing Sandrine Cailleteau is Head of Business Development & Licensing Operations of Laboratoires Fournier. Before joining Laboratoires Fournier in November 2002, she was Director Strategic Planning and Partnerships of Hesperion, a Clinical Development Organization, located in Switzerland, now part of Cerep. Prior to Hesperion, she spent 10 years with Sanofi, and then Sanofi-Synthelabo in different positions, the latest being Licensing Project Director at Paris headquarters. Her prior different positions at Sanofi included Manager Investor Relations, M&A and Strategic Planning Manager, where she was responsible for both acquisitions and divestitures, and then Public Affairs (where she spent 3 years in Washington DC, representing Sanofi with International Organizations and notably the World Bank). She graduated in Political Sciences from IEP Paris and holds an MBA from the French Chamber of Commerce of Paris (HEC-ISA). |
 |
| Dr.
Andrew Barber, Global Licensing
& Business Development Leader, Corporate Business Development Born in England, Andrew Barber earned a BSc. and Ph.D. in Neuroscience before taking up a position as a Scientific Assistant at the University of Munich, Germany in 1982. After joining the firm Merck in Darmstadt he worked in the CNS research department where he authored or co-authored numerous publications in peer-reviewed international science journals, and was the co-author of various patents in the fields of novel analgesics, opiates, new serotonergic and amino acid antagonists, and neuroprotectants. In 1998 he changed to Business Development where he has been supporting Merck Pharma goals through his activities in the licensing area. Since June 2002 he has been the person within Business Development at Darmstadt responsible for the area of High Potential Products, non-core projects with an emphasis on further development within the framework of partnerships. |
 |
| Adi
Seffer, Partner Adi Seffer is head of the Morgan Lewis' Technology Practice in Frankfurt. His practice focuses on tech-driven transactions for Technology (TMT) - and Biotechnology clients and the financial community. He handles e-commerce matters, IP/IT and Biotech related agreements, M&A Transactions and private and public financing. Mr. Seffer is nominated by Legal Media Group, London as one of only 30 lawyers worldwide as a leading lawyer in both Telecoms and IT. He is a regular speaker at seminars on tech- and biotech related topics as well as public and private financing. Mr. Seffer's transnational dispute experience includes ICC arbitration involving U.S. client and other foreign clients, acting as a panel arbitrator in a German arbitration, and several ad hoc arbitrations under various German arbitration rules. His legal education was supplemented by training in International Law in London (1983), Comparison of Laws in Strasbourg, France (1984 and 1985), and International Investments in Barcelona, Spain (1989). Mr. Seffer is a German national and admitted to practice in Germany to the Bar of Frankfurt. Contact Adi Seffer: Email: aseffer@morganlewis.com Phone: (+48 69) 71 40 07-66. |
 |
| Anthony
Warnock-Smith, Partner Anthony Warnock-Smith is a partner in the Business & Finance practice group based in London. His practice focuses on government regulation and business transactions involving the pharmaceutical, medical device, cosmetics, veterinary drug, and foods and food additives industries. Mr. Warnock-Smith has 30 years of experience in regulatory matters, as well as commercial agreements and transactions in Europe. His government regulation experience involves the full range of services of interest to these industries, from clinical trial and product development issues, to marketing and allied reimbursement, product liability and other trade regulation matters. He is also experienced in joint ventures, mergers and acquisitions, European Union competition law, restructurings, distribution agreements, technology licensing and strategic partnering for these industries. From 1973 until 1996, Mr. Warnock-Smith worked in the legal department of the pharmaceutical company Sterling Winthrop (later Sanofi - Synthelabo), rising to vice president of legal services in Europe. |
 |
| Dr.
Christian Zschocke, Managing
Partner Christian O. Zschocke is the managing partner of the Frankfurt office. Mr. Zschocke’s practice is concentrated in the area of mergers and acquisitions, and EU and German antitrust law, and securities law. Mr. Zschocke is a regular speaker at seminars, and an author of numerous publications on corporate and antitrust law, including a commentary on the German Takeover Code. The publishers of Germany’s leading antitrust review have turned to him as the editor responsible for the section on international antitrust developments. Prior to joining the firm in 1997, Mr. Zschocke worked in the London, Brussels and Frankfurt offices of a New York-based international law firm. Mr. Zschocke also served as a trainee at the Commission of the European Communities, Directorate General IV for Competition, and for law firms in Barcelona, Buenos Aires, Hamburg and Paris. Mr. Zschocke has been appointed by the European Banking Federation and the Federation of European Stock Exchanges, to be one of six members of a European "Committee of Practitioners on Takeover Regulation" to contribute to the future European Takeover Directive as well as to serve as a platform for communication for the legislative process. Mr. Zschocke is a German national. Mr. Zschocke is admitted to practice in Germany. |
 |
| Denise
Pollard-Knight, Head of Healthcare Dr. Denise Pollard-Knight is Head of Phase4 Ventures a subsidiary of Nomura International. She leads a team responsible for investing Nomura's own capital in US and European biotechnology companies. She currently serves as a Board Member for both Idenix, Viacell and Develogen. Prior to joining Nomura in 1999, Dr. Pollard-Knight was a member of the Bioscience unit of Rothschild Asset Management, a unit managing funds of more than $500M invested globally in early and late stage biotechnology companies. In 1993, Dr. Pollard-Knight joined Scientific Generics, a public strategic consulting company where she was responsible for the Life Sciences division and a member of the board of directors. Prior to Scientific Generics, Dr Pollard-Knight held R&D management positions of increasing responsibility at Amersham-Pharmacia and Fisons plc. Dr. Pollard-Knight holds a Ph.D. and BSc (Hons) in Biochemistry from the University of Birmingham in England and was a postdoctoral Fulbright Scholar at the University of California, Berkeley. |
 |
| Martin
Friedman, Head of Pharma M&A Martin Friedman is the Head of M&A and equity
collaborations for the Pharmaceutical business at Novartis, |
 |
| Dennis
Purcell, Senior Managing Director Dennis joined the Perseus Soros BioPharmaceutical Fund, L.P. February 2000 as Senior Managing Partner. He is responsible for the overall management of the fund, which is dedicated to making private equity investments in the life sciences industry. Prior to this, Dennis served as Managing Director of Life Sciences Investment Banking at Chase H&Q (formerly Hambrecht & Quist) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceuticals, biotechnology and medical products industries. During his tenure, H&Q was cited by BioWorld and other industry publications as the leading underwriter of life sciences securities from 1995 through 2000. Dennis has also often been cited as one of the sector’s leaders. He was honored in the “Biotech Hall of Fame” by Genetic Engineering News in June 1998 and named to the Biotechnology All-Stars list by Forbes ASAP in May 1999. Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. Dennis currently serves on the Bioethics Committee of The Biotechnology Organization. He is a member of the Editorial Board of Biotechnology Investors Forum, serves on the Board of Directors of the New York Biotechnology Association and is a member of the Biological and Molecular Pharmacology Advisory Council at Harvard Medical School. Dennis also serves as a director of Auxilium Pharmaceuticals, Inc., Cengent, Inc., and Valentis, Inc. He received a Bachelor of Science in Economics and Accounting from the University of Delaware and an M.B.A. from Harvard University. ALSO... |
 |
| Hans
van Swaay, Head of Private Equity Hans Van Swaay has 17 years experience in private equity with investments in Switzerland, Germany, France, Holland and the United Kingdom. Prior to joining Pictet in 2000, he was a managing director with UBS and responsible for its German private equity activities. During his earlier private equity career he was respectively managing director with Merifin, a Belgium and Swiss based private European private equity operation and a partner with Lowe Finance, a Swiss based private equity house with investments throughout Europe. During his private equity career he has on occasion assumed the operating role of CEO, when investee companies required major restructuring. He holds a BSc. from Leiden University (Holland), an MSc. from Leeds University (UK) and an MBA with honours from IMD (Switzerland). Prior to his private equity career he worked for 6 years with Shell in project finance, finance and general management positions in the UK. Before taking his MBA, he worked for 3 years for HBG, a major Dutch construction company, as an engineering geologist in Holland and Saudi Arabia. |
 |
| Dr.
Frank Grams, Global Alliance Director
Frank has been a Global Alliance Director at Roche since 2002. In this function he covers all aspects of Research Licensing for late stage technologies and several disease areas. He joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001. Prior to joining that group, Frank worked in various Research functions in Roche and at Bushranger Mannheim GmbH. Frank has a degree in chemistry from the University of Heidelberg, and he earned his Ph.D. from the Technical University of Munich as member of the group of Nobel laureate Robert Huber at the Max-Planck-Institute for Biochemistry at Martinsried. |
 |
| Jonathan
Freeman, Director, Strategy &
Portfolio Evaluation Corporate Business Development Jonathan is involved in defining the strategic direction within Serono’s corporate and business development, identifying future therapeutic areas and technologies to generate growth and both isolating and valuing discrete project or company-based opportunities that align with this vision. In addition, he is responsible for the valuation of the internal in-market and developmental pipeline. Previously, he over-saw several collaborative clinical and pre-clinical programs and directed corporate out-licensing. Jonathan holds a first-class degree in Biochemistry from Cambridge University, a PhD in Molecular Pharmacology from the ICRF, a Finance MBA from Geneva Webster University and has previously worked in both private and academic research organizations, consultancy and financial operations. |
 |
| Antoine
Papiernik, Managing Partner Antoine Papiernik is managing partner at Sofinnova
Partners and invests in life sciences. He joined Sofinnova Partners
in 1997. |
 |
| Marc
Zahn, Vice President, Head of Marketing &
Sales Marc Zahn joined the SWX Swiss Exchange beginning of 2004. He is responsible for Marketing and Sales for both SWX Swiss Exchange and virt-x, the pan-European Stock Exchange in London. Prior to joining SWX Swiss Exchange, Marc was
the CEO of an online broker, spent 7 years in the IT/Telecoms sector
holding senior management roles in Marketing, Sales and Strategic
Business Development. He spent 4 years in the USA building up a
marketing and sales organisation for Ciba-Geigy's Industrial Division
(Mettler-Toledo). He started his professional career with Credit
Suisse, where he worked in the commercial loans department for the
UK, Ireland and South Africa. |
 |
| Dr.
Alexandra Goll, General Partner
Dr. Alexandra Goll has been responsible for about 10 TVM investments since she joined the company in early 1998. She represented the interests of TVM at Actelion Ltd. (Allschwil, CH) until the IPO and was a member of the Supervisory Board of Idenix Pharmaceuticals, Inc. (Cambridge, MA) until the closure of the Novartis transaction in May 2003. Currently she serves on the Board of Arrow Therapeutics Ltd. (London, UK), Addex Pharmaceuticals Ltd. (Geneva, CH), Axxima Pharmaceuticals AG (Martinsried, Germany), MediGene AG (Martinsried, GER), Pharmasset Ltd. (Atlanta, GA). She also represents the interests of TVM at Ark Therapeutics Ltd. (London, UK), Wilex AG (Munich, Germany) and Zeptosens AG (Witterswill, CH). Prior to her affiliation with TVM, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Hoffmann-La Roche in Basel. She holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine. |
 |
| Nicholas
J. Lowcock, Managing Director Nick Lowcock joined the Warburg Pincus Healthcare Group in 1994. Based in London, he is responsible for the firm’s European healthcare investment activities. This includes a portfolio with an estimated market value of around $1 billion and a rate of new investment averaging over $100 million per year. Mr. Lowcock spent the first four years of his career with Warburg Pincus in New York. He received an MBA (with distinction) from the Wharton School of the University of Pennsylvania and a BA (first class) in Experimental Psychology from Oxford University. His previous experience includes two years as a consultant at The Boston Consulting Group in New York and four years in the Pharmaceutical Industry in the United Kingdom. Mr. Lowcock currently serves on the board of directors of Zentiva, Eurand, Strakan, Proskelia, Domus and PharmaIdea. He is also a trustee of Project Hope UK, a charity devoted to improving healthcare in developing nations. Mr. Lowcock is a member of the Executive Management Group of Warburg Pincus. |
 |
| William
van Eesteren, Director Mr. van Eesteren sources and conducts due diligence on private equity fund investments in Europe. Prior to joining Wilshire, he worked in investment banking, most recently as Vice President with ING Barings. Mr. Van Eesteren was also previously with NationsBank and Bank of America in London. He received a MSc degree in Business Administration from Erasmus University in Rotterdam. Mr. Eesteren joined Wilshire in 2001. |
 |